Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01349075 · ClinicalTrials.gov registry record
TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma
A clinical trial, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Completed
- Registry status
- 474
- Enrollment target
NCT01349075: Completed study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
NCT01349075 is a clinical trial that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 474 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01349075 has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- COMPLETED
- Registry status
- 474 participants
- Enrollment target
Study Summary
TheraSphere is a medical device containing yttrium-90 (Y-90) a radioactive material that has been used to treat liver tumors. When Y-90 is put into very tiny glass beads (TheraSphere), it can be injected into the liver through a blood vessel. This allows a large local dose of radiation to be delivered to the tumor with less risk of toxic effects from radiation to other parts of the body or to healthy liver tissue.
Primary Outcome
Diagnostic imaging studies for assessment of tumor response will be performed according to usual standard of care as established by the referring oncologist. The principal clinician will be able to get a preliminary evaluation of tumor response in patients who return for subsequent treatment, as part of the imaging studies required for repeat safety screening of patients.
Interventions
- RADIATION TheraSphere
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 474 participants |
| Start Date | 2007-10 |
| Est. Completion | 2021-03-15 |
What the finished NCT01349075 record still lists
NCT01349075 is an observational study that tracks outcomes without assigning an intervention. The registered 474 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which TheraSphere is the first listed.
NCT01349075 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01349075 about?
NCT01349075 is a clinical study titled "TheraSphere for the Treatment of Unresectable Hepatocellular Carcinoma". TheraSphere is a medical device containing yttrium-90 (Y-90) a radioactive material that has been used to treat liver tumors. When Y-90 is put into very tiny glass beads (TheraSphere), it can be injected into the liver through a blood vessel. This allows a large local dose of radiation to be deliver...
What is the current status of trial NCT01349075?
This trial is currently completed. The enrollment target is 474 participants. The study started on 2007-10. Estimated completion is 2021-03-15.
What interventions are being tested in trial NCT01349075?
The interventions under investigation include: TheraSphere (RADIATION).
Who is sponsoring clinical trial NCT01349075?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05624996 · 474 participants · Phase 3
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
- NCT06051695 · 474 participants · Phase 1
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
- NCT06632977 · 474 participants · Phase 2
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
- NCT01788839 · 475 participants
Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia